{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:13:52Z","timestamp":1792736032070,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["381280"],"award-info":[{"award-number":["381280"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","award":["OGI-150"],"award-info":[{"award-number":["OGI-150"]}],"id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010787","name":"Genome Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013061","name":"Ontario Genomics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000142","name":"The Arthritis Society","doi-asserted-by":"crossref","award":["GC-18-001"],"award-info":[{"award-number":["GC-18-001"]}],"id":[{"id":"10.13039\/501100000142","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006126","name":"Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008459","name":"University of Calgary","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008459","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848006001"],"award-info":[{"award-number":["848006001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Approximately one third of children with JIA receive biologic therapy, but evidence on biologic therapy withdrawal is lacking. This study aims to increase our understanding of whether and when pediatric rheumatologists postpone a decision to withdraw biologic therapy in children with clinically inactive non-systemic JIA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A survey containing questions about background characteristics, treatment patterns, minimum treatment time with biologic therapy, and 16 different patient vignettes, was distributed among 83 pediatric rheumatologists in Canada and the Netherlands. For each vignette, respondents were asked whether they would withdraw biologic therapy at their minimum treatment time, and if not, how long they would continue biologic therapy. Statistical analysis included descriptive statistics, logistic and interval regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-three pediatric rheumatologists completed the survey (40% response rate). Pediatric rheumatologists are most likely to postpone the decision to withdraw biologic therapy when the child and\/or parents express a preference for continuation (OR 6.3; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), in case of a flare in the current treatment period (OR 3.9; <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and in case of uveitis in the current treatment period (OR 3.9; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). On average, biologic therapy withdrawal is initiated 6.7\u00a0months later when the child or parent prefer to continue treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patient\u2019s and parents' preferences were the strongest driver of a decision to postpone biologic therapy withdrawal in children with clinically inactive non-systemic JIA and prolongs treatment duration. These findings highlight the potential benefit of a tool to support pediatric rheumatologists, patients and parents in decision making, and can help inform its design.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00845-4","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:01:45Z","timestamp":1689076905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?"],"prefix":"10.1186","volume":"21","author":[{"given":"Janine A.","family":"van Til","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-6789","authenticated-orcid":false,"given":"Michelle M. A.","family":"Kip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J. H.","family":"Schatorj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Benseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae S. M.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G. M.","family":"Groothuis-Oudshoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Warta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the UCAN CAN-DU, UCAN CURE consortia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"5","key":"845_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","volume":"46","author":"R Davies","year":"2017","unstructured":"Davies R, Gaynor D, Hyrich KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Semin Arthritis Rheum. 2017;46(5):584\u201393.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"845_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","volume":"21","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature. Paediatr Drugs. 2019;21(6):469\u201392.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"845_CR3","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"845_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.berh.2018.01.001","volume":"31","author":"G Giancane","year":"2017","unstructured":"Giancane G, Alongi A, Rosina S, Tibaldi J, Consolaro A, Ravelli A. Recent therapeutic advances in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2017;31(4):476\u201387.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"845_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/14737167.2021.1857241","volume":"21","author":"MMA Kip","year":"2021","unstructured":"Kip MMA, de Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, et al. Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):975\u201384.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"845_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717\u201334.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"845_CR7","unstructured":"Nederlandse Vereniging voor Kindergeneeskunde. Richtlijn medicamenteuze behandeling van kinderen met juveniele idiopathische artritis. Version 2. 2017."},{"issue":"3","key":"845_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol. 2017;44(3):352\u201360.","journal-title":"J Rheumatol"},{"issue":"3","key":"845_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40744-021-00331-x","volume":"8","author":"LR Grazziotin","year":"2021","unstructured":"Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, et al. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatol Ther. 2021;8(3):1303\u201322.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"845_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12969-022-00769-5","volume":"20","author":"J Gieling","year":"2022","unstructured":"Gieling J, van den Bemt B, Hoppenreijs E, Schatorje E. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors. Pediatr Rheumatol Online J. 2022;20(1):109.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"845_CR11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/acr.23435","volume":"70","author":"G Simonini","year":"2018","unstructured":"Simonini G, Ferrara G, Pontikaki I, Scoccimarro E, Giani T, Taddio A, et al. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration. Arthritis Care Res (Hoboken). 2018;70(7):1046\u201351.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"845_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM, Watanabe Duffy K, Boire G, Shiff N, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75(6):1092\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"845_CR13","first-page":"229","volume":"45","author":"SA Azevedo","year":"2020","unstructured":"Azevedo SA, Ramos Rodrigues J, Guimaraes F, Almeida D, Pinto AS, Parente H, et al. Strategies for the withdrawal of classic and biological DMARD in clinically inactive patients with juvenile idiopathic arthritis. Acta Reumatol Port. 2020;45(3):229\u201332.","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"845_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40271-022-00575-x","volume":"15","author":"GR Currie","year":"2022","unstructured":"Currie GR, Pham T, Twilt M, MJ IJ, Hull PM, Kip MMA, et al. Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient. 2022;15(5):599\u2013609.","journal-title":"Patient"},{"key":"845_CR15","doi-asserted-by":"publisher","unstructured":"Currie GR, Groothuis-Oudshoorn CGM, Twilt M, Kip MMA, IJzerman MJ, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung R, Marshall DA. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey. Clin Rheumatol. 2023. https:\/\/doi.org\/10.1007\/s10067-023-06616-6.\u00a0Epub ahead of print. PMID: 37202606.","DOI":"10.1007\/s10067-023-06616-6"},{"issue":"2","key":"845_CR16","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"8","key":"845_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2011.02.001","volume":"10","author":"YT Lin","year":"2011","unstructured":"Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular\/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10(8):482\u20139.","journal-title":"Autoimmun Rev"},{"key":"845_CR18","volume-title":"R: A languange and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team. R: A languange and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019."},{"key":"845_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/OARRR.S174408","volume":"11","author":"DC Fair","year":"2019","unstructured":"Fair DC, Rodriguez M, Knight AM, Rubinstein TB. Depression And Anxiety In Patients With Juvenile Idiopathic Arthritis: Current Insights And Impact On Quality Of Life A Systematic Review. Open Access Rheumatol. 2019;11:237\u201352.","journal-title":"Open Access Rheumatol"},{"issue":"9","key":"845_CR20","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3899\/jrheum.120089","volume":"39","author":"CM Leblanc","year":"2012","unstructured":"Leblanc CM, Lang B, Bencivenga A, Chetaille AL, Dancey P, Dent P, et al. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol. 2012;39(9):1875\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"845_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74(4):553\u201369.","journal-title":"Arthritis Rheumatol"},{"key":"845_CR22","doi-asserted-by":"publisher","unstructured":"Kip MMA, de Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology (Oxford). 2023;62(SI2):SI170-80. https:\/\/doi.org\/10.1093\/rheumatology\/keac299.","DOI":"10.1093\/rheumatology\/keac299"},{"issue":"1","key":"845_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12969-022-00682-x","volume":"20","author":"LR Grazziotin","year":"2022","unstructured":"Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, et al. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatr Rheumatol Online J. 2022;20(1):25.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"845_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/BOR.0000000000000727","volume":"32","author":"IR Klein-Wieringa","year":"2020","unstructured":"Klein-Wieringa IR, Brinkman DMC, Ten Cate R, Hissink Muller PCE. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheumatol. 2020;32(5):403\u201313.","journal-title":"Curr Opin Rheumatol"},{"key":"845_CR25","doi-asserted-by":"publisher","unstructured":"Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, Holzinger D, Stanevica V, Swart JF, Cabral DA, Brunner HI, Foell D. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis. 2022;81(7):990-7. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222029.","DOI":"10.1136\/annrheumdis-2021-222029"},{"key":"845_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41927-019-0070-y","volume":"3","author":"KF Baker","year":"2019","unstructured":"Baker KF, Isaacs JD, Thompson B. \u201cLiving a normal life\u201d: a qualitative study of patients\u2019 views of medication withdrawal in rheumatoid arthritis. BMC Rheumatol. 2019;3:2.","journal-title":"BMC Rheumatol"},{"issue":"10","key":"845_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","volume":"98","author":"AM Stiggelbout","year":"2015","unstructured":"Stiggelbout AM, Pieterse AH, De Haes JC. Shared decision making: Concepts, evidence, and practice. Patient Educ Couns. 2015;98(10):1172\u20139.","journal-title":"Patient Educ Couns"},{"issue":"2","key":"845_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ijchp.2014.12.001","volume":"15","author":"SC Evans","year":"2015","unstructured":"Evans SC, Roberts MC, Keeley JW, Blossom JB, Amaro CM, Garcia AM, et al. Vignette methodologies for studying clinicians\u2019 decision-making: Validity, utility, and application in ICD-11 field studies. Int J Clin Health Psychol. 2015;15(2):160\u201370.","journal-title":"Int J Clin Health Psychol"},{"key":"845_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","volume":"15","author":"CT Cunningham","year":"2015","unstructured":"Cunningham CT, Quan H, Hemmelgarn B, Noseworthy T, Beck CA, Dixon E, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15:32.","journal-title":"BMC Med Res Methodol"},{"key":"845_CR30","doi-asserted-by":"publisher","first-page":"690680","DOI":"10.3389\/fsurg.2021.690680","volume":"8","author":"R de Koning","year":"2021","unstructured":"de Koning R, Egiz A, Kotecha J, Ciuculete AC, Ooi SZY, Bankole NDA, et al. Survey Fatigue During the COVID-19 Pandemic: An Analysis of Neurosurgery Survey Response Rates. Front Surg. 2021;8:690680.","journal-title":"Front Surg"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:04:34Z","timestamp":1689077074000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00845-4","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants. The study was approved by the ethical committee of the faculty of Behavioural, Management and Social Sciences of the University of Twente (no. 200741).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS reports grants from SOBI and consulting fee from Amgen, outside the submitted work; SV reports grants and personal fees from SOBI and Novartis during the conduct of the study; DM reports non-financial support from consultancy (Illumina) and ISPOR, and personal fees from Analytica, outside the submitted work; MIJ reports institutional support from Illumina; JvT, MK, ES, GC, MT, SB, NW, RY, CGO and SW have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}